Return to Search
EN
Early diagnosis and appropriate treatment enable many individuals with Familial Mediterranean Fever (FMF) to lead normal lives. A balanced diet, regular exercise, weight management, and a healthy, stress-free lifestyle can help manage pain and maintain overall well-being.
While there is no definitive cure for FMF, the primary aim of treatment is to control and prevent its symptoms and complications. The main medication used for this purpose is colchicine.
Colchicine
Colchicine, when used in adequate doses, significantly reduces the frequency of FMF attacks. It is also crucial in preventing amyloidosis, a serious long-term complication of FMF, as demonstrated by important studies. However, its potential effect on azoospermia is still under investigation.
* Dosage and Administration: Colchicine therapy is typically lifelong for FMF patients. Dosages vary based on age and symptom severity. For children under five, a daily dose of 0.03-0.07 mg/kg is recommended, with the optimal dose determined by a physician. As the child grows, the dose can be increased in 0.5 mg increments. For children over ten and adults, 1 mg of colchicine is generally considered ideal.
Patients with more complex disease, such as frequent attacks or existing amyloidosis, may receive higher doses (2 to 2.5 mg) if tolerated and if liver and kidney functions are normal. Patients who have undergone kidney transplantation due to end-stage renal disease related to amyloidosis should continue colchicine post-transplant.
Pregnant or breastfeeding women typically do not need to discontinue colchicine. Children treated with colchicine should undergo blood and urine tests at least twice a year.
* Side Effects: The most common side effects of colchicine are diarrhea, bloating, and abdominal cramps, with diarrhea being particularly frequent, especially at higher doses. If diarrhea causes patients to discontinue the medication, dividing the daily dose into two or three smaller doses can be considered.
Less common side effects include myelosuppression, hepatotoxicity, nephrotoxicity, myopathy, neuropathy, and hypersensitivity reactions.
Rarely, colchicine can cause muscle weakness, particularly when taken concurrently with certain antibiotics (e.g., erythromycin from the macrolide family) or statins (cholesterol-lowering drugs). Therefore, co-administration of these medications with colchicine requires careful consideration.
* Colchicine Resistance: Colchicine resistance is suspected if, despite adherence to treatment with the maximum tolerable dose (up to 3 mg in adults), the frequency and severity of attacks do not improve, and acute phase reactant levels in the blood remain elevated between attacks. In such cases, the colchicine dose may be increased, or different treatment options should be evaluated. Patients who experience one or two attacks per month despite taking the maximum tolerated and regular dose of colchicine for six months are considered unresponsive to colchicine.
Alternative Anti-Inflammatory Medications
For patients who are unresponsive to or intolerant of colchicine, alternative therapeutic approaches can be explored. These may include medications that block interleukin-1 (IL-1), a protein involved in inflammation, such as IL-1 receptor antagonists (e.g., anakinra). In recent years, TNF inhibitors and IL-1 inhibition therapies have gained prominence in FMF treatment.
What is the treatment for Familial Mediterranean Fever?
While there is no definitive cure for FMF, the primary aim of treatment is to control and prevent its symptoms and complications. The main medication used for this purpose is colchicine.
Colchicine
Colchicine, when used in adequate doses, significantly reduces the frequency of FMF attacks. It is also crucial in preventing amyloidosis, a serious long-term complication of FMF, as demonstrated by important studies. However, its potential effect on azoospermia is still under investigation.
* Dosage and Administration: Colchicine therapy is typically lifelong for FMF patients. Dosages vary based on age and symptom severity. For children under five, a daily dose of 0.03-0.07 mg/kg is recommended, with the optimal dose determined by a physician. As the child grows, the dose can be increased in 0.5 mg increments. For children over ten and adults, 1 mg of colchicine is generally considered ideal.
Patients with more complex disease, such as frequent attacks or existing amyloidosis, may receive higher doses (2 to 2.5 mg) if tolerated and if liver and kidney functions are normal. Patients who have undergone kidney transplantation due to end-stage renal disease related to amyloidosis should continue colchicine post-transplant.
Pregnant or breastfeeding women typically do not need to discontinue colchicine. Children treated with colchicine should undergo blood and urine tests at least twice a year.
* Side Effects: The most common side effects of colchicine are diarrhea, bloating, and abdominal cramps, with diarrhea being particularly frequent, especially at higher doses. If diarrhea causes patients to discontinue the medication, dividing the daily dose into two or three smaller doses can be considered.
Less common side effects include myelosuppression, hepatotoxicity, nephrotoxicity, myopathy, neuropathy, and hypersensitivity reactions.
Rarely, colchicine can cause muscle weakness, particularly when taken concurrently with certain antibiotics (e.g., erythromycin from the macrolide family) or statins (cholesterol-lowering drugs). Therefore, co-administration of these medications with colchicine requires careful consideration.
* Colchicine Resistance: Colchicine resistance is suspected if, despite adherence to treatment with the maximum tolerable dose (up to 3 mg in adults), the frequency and severity of attacks do not improve, and acute phase reactant levels in the blood remain elevated between attacks. In such cases, the colchicine dose may be increased, or different treatment options should be evaluated. Patients who experience one or two attacks per month despite taking the maximum tolerated and regular dose of colchicine for six months are considered unresponsive to colchicine.
Alternative Anti-Inflammatory Medications
For patients who are unresponsive to or intolerant of colchicine, alternative therapeutic approaches can be explored. These may include medications that block interleukin-1 (IL-1), a protein involved in inflammation, such as IL-1 receptor antagonists (e.g., anakinra). In recent years, TNF inhibitors and IL-1 inhibition therapies have gained prominence in FMF treatment.